Arcadia Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Arcadia Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34K	Hold	3	–	–	﹤0.01%	241
2025 Q4	$1.36K	Buy	+3	New	+$1.29K	﹤0.01%	249
2024 Q1	–	Sell	-221	Closed	-$89.9K	–	336
2023 Q4	$89.9K	Hold	221	–	–	0.02%	172
2023 Q3	$76.9K	Hold	221	–	–	0.02%	178
2023 Q2	$77.8K	Buy	+221	New	+$74.5K	0.02%	189
2018 Q3	–	Sell	-160	Closed	-$27K	–	331
2018 Q2	$27K	Hold	160	–	–	0.01%	267
2018 Q1	$26K	Hold	160	–	–	0.01%	271
2017 Q4	$24K	Hold	160	–	–	0.01%	284
2017 Q3	$24K	Hold	160	–	–	0.01%	287
2017 Q2	$21K	Hold	160	–	–	0.01%	288
2017 Q1	$17K	Hold	160	–	–	0.01%	341
2016 Q4	$12K	Hold	160	–	–	﹤0.01%	282
2016 Q3	$14K	Hold	160	–	–	﹤0.01%	290
2016 Q2	$14K	Hold	160	–	–	﹤0.01%	380
2016 Q1	$13K	Hold	160	–	–	﹤0.01%	247
2015 Q4	$20K	Buy	+160	New	+$19.3K	0.01%	221

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arcadia Investment Management's VRTX Position: Q1 2026 in Review

Arcadia Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 3 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

Arcadia Investment Management first reported a position in VRTX in Q4 2015 and has held it in 16 quarters since. The position peaked at $89.9K in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Arcadia Investment Management held 3 shares of Vertex Pharmaceuticals worth $1.34K as of Q1 2026.
Arcadia Investment Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Arcadia Investment Management's portfolio in Q1 2026, its #241 holding.
Arcadia Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
Arcadia Investment Management's Vertex Pharmaceuticals position peaked at $89.9K in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Arcadia Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.